F500 2019-Merck
SALT LAKE CITY, UT - APRIL 26: In this photo illustration sterile water is prepared for a one dose bottle of measles, mumps and rubella virus vaccine, made by MERCK, at the Salt Lake County Health Department on April 26, 2019 in Salt Lake City, Utah. (Photo Illustration by George Frey/Getty Images)George Frey—Getty Images
  • Previous Rank
    78
  • Revenues ($M)
    42294.0
  • Revenue Percent Change
    5.4
  • Profits ($M)
    6220.0
  • Profits Percent Change
    159.8
  • Assets ($M)
    82637.0
  • Employees
    69000

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

Company Info

CEOKenneth C. Frazier
CEO TitleChairman, President & Chief Executive Officer
SectorHealth Care
IndustryPharmaceuticals
HQ LocationKenilworth, N.J.
Websitewww.merck.com
Years on Fortune 500 List65
Employees69,000

Key Financials (Last Fiscal Year)

Revenues ($M)$42,294
Profits ($M)$6,220
Assets ($M)$82,637
Total Stockholder Equity ($M)$26,701

Profit Ratios

Profit as % of Revenues14.7%
Profits as % of Assets7.5%
Profits as % of Stockholder Equity23.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)2
EPS % Change (from 2017)166.7%
EPS % Change (5 year annual rate)9.6%
EPS % Change (10 year annual rate)-4.4%

Total Return

Total Return to Investors (2018)40.2%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)13.8%